Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

FLT3 Inhibition in acute myeloid leukaemia - current knowledge and future prospects

Hogan, Francesca L., Williams, Victoria and Knapper, Steven ORCID: 2020. FLT3 Inhibition in acute myeloid leukaemia - current knowledge and future prospects. Current Cancer Drug Targets 20 (7) , pp. 513-531. 10.2174/1570163817666200518075820

[thumbnail of KNAPPER, STEVE - FLT3 inhibition in AML - current knowledge and future prospects (edits in response to review comments).pdf] PDF - Accepted Post-Print Version
Download (497kB)


Activating mutations of FMS-like tyrosine kinase 3 (FLT3) are present in 30% of acute myeloid leukaemia (AML) patients at diagnosis and confer an adverse clinical prognosis. Mutated FLT3 has emerged as a viable therapeutic target and a number of FLT3-directed tyrosine kinase inhibitors have progressed through clinical development over the last 10-15 years. The last two years have seen United States Food and Drug Administration (US FDA) approvals of the multi-kinase inhibitor midostaurin for newly-diagnosed FLT3-mutated patients, when used in combination with intensive chemotherapy, and of the more FLT3-selective agent gilteritinib, used as monotherapy, for patients with relapsed or treatment-refractory FLT3-mutated AML. The ‘second generation’ agents, quizartinib and crenolanib, are also at advanced stages of clinical development. Significant challenges remain in negotiating a variety of potential acquired drug resistance mechanisms and in optimizing sequencing of FLT3 inhibitory drugs with existing and novel treatment approaches in different clinical settings, including frontline therapy, relapsed/refractory disease, and maintenance treatment. In this review, the biology of FLT3, the clinical challenge posed by FLT3-mutated AML, the developmental history of the key FLT3-inhibitory compounds, mechanisms of disease resistance, and the future outlook for this group of agents, including current and planned clinical trials, is discussed.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Publisher: Bentham Science Publishers
ISSN: 1568-0096
Date of First Compliant Deposit: 31 August 2021
Date of Acceptance: 29 March 2020
Last Modified: 07 Nov 2023 07:06

Citation Data

Cited 5 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item


Downloads per month over past year

View more statistics